Clinical outcomes and complications of single anastomosis duodenal-ileal bypass with sleeve gastrectomy: A 2-year follow-up study in Bogotá, Colombia.

BACKGROUND: The global prevalence of obesity has increased over the past 40 years, and bariatric surgery has proven to be the most effective therapy for long-term weight loss. Its principles are based on modifying the brain-gut axis by altering the gastrointestinal anatomy and affecting the function of gastrointestinal hormones, thereby modifying satiety signals. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) combines both techniques and has become an alternative to gastric bypass and biliopancreatic diversion procedures for treating severe obesity and associated metabolic diseases in selected patients. AIM: To describe the outcomes and complications of SADI-S. METHODS: We retrospectively analyzed the data of patients who underwent SADI-S laparoscopically at the Clínica Reina Sofía in Bogotá, Colombia. This study assessed the therapeutic effectiveness of SADI-S in terms of short-term preoperative clinical characteristics, postoperative complications, comorbidities, nutritional defi-ciencies, and intraoperative complications during a 2-year follow-up. RESULTS: Sixty-one patients with a mean body mass index (BMI) of 50 ± 7.1 kg/m2 underwent laparoscopic SADI-S. The mean operative time and hospital stays were 143.8 ± 42 min and 2.3 ± 0.8 d, respectively. The mean follow-up period was 18 mo, and the mean BMI decreased to 28.5 ± 12.2 kg/m2. The excess BMI loss was 41.8% ± 13.5%, and the weight loss percentage was 81.1% ± 17.0%. Resolution of obesity-related comorbidities, including type 2 diabetes mellitus, hypertension, dyslipidemia, and obstructive sleep apnea, was achieved and defined as complete or partial remission. No intraoperative complications were observed. Short-term complications were observed in four (6.8%) patients. However, larger studies with longer follow-up periods are required to draw definitive conclusions. CONCLUSION: SADI-S has a low intraoperative and postoperative complication rate and is effective for weight loss and improving obesity-related comorbidities, including hypertension, type 2 diabetes mellitus, dyslipidemia, and sleep apnea syndrome.

Estudio sobre el valor diagnóstico de la tuberculina / Study about the diagnostic value of tuberculin

Se realizó un estudio de 2 años de duración, buscando determinar el valor diagnóstico de PPD en un grupo de 174 niños menores de 15 años, para lo cual se dividieron en dos grupos, los que tenian BCG y los que no. Se observó que los que tenían BCG en el 100 por ciento fueron tuberculino negativos contra 97.24 por ciento de negatividad en los que tenían antecedente de BCG. Al aplicar a estos niños la vacuna BCG y realizar otra lectura del PPD 2 meses después el 78.26 por ciento fueron tuberculino positivos. Sin embargo al practicar otra lectura 8 meses después se encontró que el 72.97 por ciento es nuevamente tuberculino negativo. En un grupo de 33 niños menores de 15 años y con diagnóstico de TBC se observó que el 69.7 por ciento son tuberculino positivos. Se concluyó que la prueba PPD si tiene valor para la sospecha de infección por micobacteria aún en los niños con BCG siempre y cuando haya transcurrido mas de 2 años de su aplicación